Search clinical trials for: Interferon-beta 1b

Total 947 results

Bayer
Biogen Netherlands B.V; Novartis Europharm Limited; Merck Europe B.V.

Not yet recruiting

An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden (INFORM)

Multiple Sclerosis (MS)

Sweden, Finland
Novartis Pharmaceuticals

Recruiting

Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS (STHENOS)

Multiple Sclerosis

Germany, Spain, Italy, France, United Kingdom
Bayer

Completed

US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector

Multiple Sclerosis

United States
Bayer

Completed

Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon (BETAPREDICT)

Multiple Sclerosis

Germany
Biogen

Withdrawn

Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)

Relapsing Multiple Sclerosis
University Hospital, Bordeaux
University of Bordeaux

Completed

Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation (COVERAGEFrance)

Corona Virus Infection | Sars-CoV2

France
National Institute of Allergy and Infectious Diseases...

Completed

Open Label Phase I Study To Evaluate the Safety of Combination Therapy With AZT and Interferon-Beta in Patients With AIDS Related Kaposi's Sarcoma

HIV Infections | Sarcoma, Kaposi

United States
The University of Hong Kong

Unknown

IFN-beta 1b and Remdesivir for COVID19

Covid19

Hong Kong
Biogen

Completed

Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy (PLENO)

Relapsing Remitting Multiple Sclerosis

Portugal
EMD Serono Research & Development Institute, Inc.

Completed

A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD) (ONWARD)

Multiple Sclerosis

United States, Italy, Russian Federation, Spain
The University of Hong Kong
Hospital Authority, Hong Kong

Unknown

IFN Beta-1b and Ribavirin for Covid-19

Covid19

Hong Kong
The University of Hong Kong

Completed

Double Therapy With IFN-beta 1b and Hydroxychloroquine

COVID

Hong Kong
The University of Hong Kong

Unknown

Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19

COVID-19

China
King Abdullah International Medical Research Center

Completed

MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b (MIRACLE)

Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

Saudi Arabia
Shahid Beheshti University of Medical Sciences

Completed

An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial (COVIFERON)

COVID-19

Iran, Islamic Republic of
The University of Hong Kong
Hospital Authority, Hong Kong

Completed

Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment

Novel Coronavirus Infection

Hong Kong
Biogen
AMS Advanced Medical Services GmbH

Completed

A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis (PERFECT)

Multiple Sclerosis, Relapsing-Remitting

Germany
Bayer
Novartis Pharmaceuticals; Biogen; EPID Research; Merck Serono Europe Ltd

Completed

EPID Multiple Sclerosis Pregnancy Study

Multiple Sclerosis

Finland
Bayer

Completed

Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study (PROmyBETAapp)

Multiple Sclerosis

Germany
Bayer

Completed

Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction

Multiple Sclerosis, Relapsing-Remitting

United States
Bayer

Completed

Betaferon Use in Children and Adolescents With Multiple Sclerosis

Multiple Sclerosis

Russian Federation
Bayer

Completed

Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b (ADHERENCE)

Multiple Sclerosis
Bayer

Completed

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis (CogniPlus)

Multiple Sclerosis

Turkey, Czechia, Hungary, Israel, Germany, France, Belgium, Greece, Netherlands, Egypt, Kazakhstan, Argentina, Portugal, Algeria, Saudi Arabia, Albania, Tunisia
Bayer

Completed

Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon (BetaSleep)

Multiple Sclerosis

Germany
Bayer

Completed

BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon

Multiple Sclerosis, Relapsing Remitting

Belgium, Bosnia and Herzegovina, Italy, Austria, Croatia, Czechia, France, Greece, Hungary, Spain, Switzerland
Bayer

Completed

BAY86-5046 (Betaseron), Non Interventional Studies (BETAEVAL)

Multiple Sclerosis

Germany
Bayer

Completed

Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis

Multiple Sclerosis

Germany, Austria, United Kingdom, Israel, Belgium, Finland
Novartis Pharmaceuticals

Completed

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms (Cognition)

Multiple Sclerosis

Italy, Germany
Bayer

Completed

Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE) (INFLUENCE)

Multiple Sclerosis

Poland
Bayer

Completed

China Betaferon Adherence, Coping and Nurse Support Study

Multiple Sclerosis, Chronic Progressive

China
Sanofi

Completed

Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide (TERIVA)

Multiple Sclerosis

Germany, Ukraine, Canada, Austria, Russian Federation
Pfenex, Inc

Completed

Comparison Study of PF530 and Betaferon in Healthy Subjects

Multiple Sclerosis

Australia
Bayer

Completed

Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis

Multiple Sclerosis

China
Bayer

Completed

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment (BEACON)

Relapsing Remitting Multiple Sclerosis (RRMS)

China, Slovakia, France, Germany, Korea, Republic of, Saudi Arabia, Singapore, Sweden, Taiwan, Colombia, Czech Republic, Estonia, Italy, Jordan, Lebanon, Mexico, Slovenia, United Kingdom, Argentina, Bahrain, Egypt, United Arab Emirates and more
Bayer

Completed

Open, Multicentric, Prospective, Quality of Life Study in Multiple Sclerosis Patients

Multiple Sclerosis

France
Bayer

Completed

Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)

Relapsing-Remitting Multiple Sclerosis

Germany
Bayer

Completed

Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period (SEPLUS)

Multiple Sclerosis

France
Bayer

Terminated

Rehabilitation Study in MS Patients

Multiple Sclerosis, Relapsing-Remitting

France
Rutgers, The State University of New Jersey
Bayer

Completed

Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis

Multiple Sclerosis

United States
Bayer

Completed

BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose (Beyond)

Multiple Sclerosis, Relapsing-Remitting

Belgium, Israel, United States, Canada, France, Switzerland, Ireland, Italy, Australia, Spain, Austria, Germany, Brazil, Netherlands, Poland, Russian Federation, Hungary, Slovenia, Argentina, Ukraine, Greece, Sweden, Finland, Latvia, No... and more
Bayer

Withdrawn

Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)

Multiple Sclerosis

Sweden, Denmark
Bayer

Completed

Depression and Fatigue in MS Patients Treated With Betaferon. (FADO)

Multiple Sclerosis

Poland
Biogen

Withdrawn

Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy (Frequency)

Relapsing Multiple Sclerosis
Bayer

Completed

Betaferon® Regulatory Post-Marketing Surveillance

Multiple Sclerosis | Clinically Isolated System

Korea, Republic of
Bayer

Completed

Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United States
Claudio Gobbi
Ospedale Civico, Lugano

Completed

Natalizumab De-escalation With Interferon Beta-1b

Relapsing-remitting Multiple Sclerosis

Switzerland
Nancy Hammond, MD
Kansas City Area Life Sciences Institute, Inc.

Completed

Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis

Multiple Sclerosis | Low Bone Density

United States
Claudio Gobbi
Bayer

Terminated

Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis

Relapsing-remitting Multiple Sclerosis

Switzerland
Bayer

Completed

BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study

Multiple Sclerosis

Belgium, Italy, Spain, France, Germany, Canada, Switzerland, Austria, Denmark, Hungary, Netherlands, Poland, Israel, United Kingdom, Finland, Sweden, Norway, Czech Republic, Portugal, Slovenia
EMD Serono
Pfizer

Completed

RNF and Betaseron® Tolerability Study (REFORMS)

Relapsing Remitting Multiple Sclerosis (RRMS)

United States

3

Subscribe